ANI Pharmaceuticals (NASDAQ:ANIP) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Truist Financial boosted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $80.13.

ANI Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ ANIP opened at $69.82 on Thursday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business has a fifty day simple moving average of $64.24 and a two-hundred day simple moving average of $59.86. The firm has a market cap of $1.52 billion, a PE ratio of -126.95 and a beta of 0.49. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.55.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company’s stock, valued at $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock valued at $197,792. 12.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its position in shares of ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after buying an additional 473,097 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock worth $37,906,000 after acquiring an additional 30,420 shares in the last quarter. Deep Track Capital LP increased its stake in ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock valued at $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Global Alpha Capital Management Ltd. raised its stake in ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock worth $34,525,000 after acquiring an additional 88,100 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.